PRMT5 inhibitor - Mirati Therapeutics

PRMT5 inhibitor

preclinical (MTAP-deleted cancers)

from fragment-based design + SBDD

J. Med. Chem.

Mirati Therapeutics

MRTX1719 is PRMT5-MTA complex inhibitor for the treatment of MTAP-deleted cancers currently in IND-enabling studies. PRMT5 is a target of active interest with several molecules recently highlighted here. Inhibition…


 this content is exclusive to
Premium members

Upgrade to a Premium Drug Hunter membership to unlock the full content and start reading now.